Loading...
Repurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer.
Bibby, B Thiruthaneeswaran, N Yang, Lingjian McArt, D O'Reilly, P Roberts, D
Bibby, B
Thiruthaneeswaran, N
Yang, Lingjian
McArt, D
O'Reilly, P
Roberts, D
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Repurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer. 2018, 127: S195-S195 Radiother Oncol